-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $90

Benzinga·02/25/2026 14:24:43
Listen to the news
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $87 to $90.